E75.242 Niemann-Pick disease type C

Name of the Condition

• Niemann-Pick disease type C (ICD-10 Code: E75.242)

Summary

Niemann-Pick disease type C is a rare inherited lysosomal storage disorder characterized by the abnormal accumulation of lipids, particularly cholesterol and glycosphingolipids, in cells. This buildup disrupts normal cellular function, affecting organs such as the liver, spleen, and nervous system. The condition is part of a broader group of sphingolipid metabolism disorders and presents with variable clinical manifestations, including progressive neurological decline and organ dysfunction.

Causes

This disorder results from mutations in genes involved in lipid transport, specifically NPC1 or NPC2. These mutations impair the ability to move cholesterol and other lipids out of lysosomes, leading to their accumulation in tissues. Inheritance is typically autosomal recessive, meaning both copies of the gene must be mutated for the condition to manifest.

Risk Factors

• Family history of Niemann-Pick disease type C or related lysosomal storage disorders.
• Consanguineous relationships, increasing the likelihood of recessive gene mutations.
• Ethnic backgrounds with higher carrier frequencies for NPC1 or NPC2 mutations.

Symptoms

• Enlarged liver and spleen (hepatosplenomegaly).
• Progressive neurological decline, including developmental delay or regression.
• Muscle weakness, hypotonia, or spasticity.
• Seizures or abnormal eye movements (e.g., vertical supranuclear gaze palsy).
• Loss of motor skills or speech.
• Respiratory difficulties in severe cases.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and genetic testing. Key diagnostic methods include measuring cholesterol esterification in fibroblasts, assessing filipin staining in skin biopsies, and identifying mutations in the NPC1 or NPC2 genes. Imaging studies, such as MRI, may also be used to evaluate neurological involvement.

Treatment Options

Treatment focuses on managing symptoms and complications. This may include medications to address neurological symptoms, physical therapy for motor function, and supportive care for organ dysfunction. Emerging therapies, such as miglustat, aim to slow disease progression, though their effectiveness varies.

Prognosis and Follow-Up

Prognosis varies depending on the age of onset and severity of symptoms. Early-onset cases often have a more rapid progression, while later-onset cases may have a slower course. Regular follow-up with a multidisciplinary team, including neurologists and hepatologists, is essential to monitor organ function and adjust care as needed.

Complications

• Progressive neurological deterioration, including loss of motor and cognitive function.
• Liver or spleen failure due to organ enlargement.
• Respiratory complications, such as infections or respiratory failure.
• Developmental delays or regression affecting quality of life.

Lifestyle & Prevention

• Genetic counseling for families with a history of the condition to assess recurrence risk.
• Supportive care to manage symptoms and maintain quality of life.
• Avoidance of triggers that may exacerbate neurological symptoms, such as infections or stress.

When to Seek Professional Help

Seek medical attention if symptoms such as progressive neurological decline, unexplained organ enlargement, or developmental regression are observed. Early diagnosis and intervention can help manage complications and improve outcomes.

Tips for Medical Coders

When coding for Niemann-Pick disease type C (E75.242), ensure the documentation supports the specific subtype and includes details on clinical manifestations, genetic testing results, or diagnostic findings. Verify that the code aligns with the patient's confirmed diagnosis and any associated complications. Accurate coding requires clear documentation of the condition's impact on organ systems and neurological status.